ACV meeting #29, 7 January 2022

The meeting of the Advisory Committee on Vaccines (ACV).

The committee provided advice on one application:

• provisional registration of a new vaccine for active immunisation for COVID-19 (product name Nuvaxovid; active ingredient SARS-CoV-2 rS with Matrix-M adjuvant; applicant Biocelect Pty Ltd) that had been under evaluation from February 2021.

Members

Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.